ClinicalTrials.Veeva

Menu

Design and Clinical Evaluation of a School Meal With Deworming Properties

K

Kenya Medical Research Institute (KEMRI)

Status and phase

Completed
Phase 3
Phase 2

Conditions

Anemia
Helminthiasis
Tinea Capitis

Treatments

Drug: Albendazole
Dietary Supplement: uji
Dietary Supplement: Ujiplus

Study type

Interventional

Funder types

Other
Other U.S. Federal agency

Identifiers

NCT02725255
SSC2580

Details and patient eligibility

About

Intestinal parasites (IP) are among the world's neglected tropical diseases. Morbidity due to IPs is greatest in school-age children who typically have the highest burden of infection. In 2001, WHO passed a resolution for the use of large-scale mass drug administration (MDA) of antihelminthic drugs to deworm children in developing countries. Though initially effective, there is concern that MDA might not be sustainable over extended periods especially considering the large children populations and the high frequency of dosing. Further, the MDAs exert increasing drug pressure on parasite populations, a circumstance that is likely to favor parasite genotypes that can resist anthelmintic drugs. There is hence a need for alternatives that are not only affordable and sustainable but easier to implement in the long term with a minimal chance of development of resistance. The investigators propose to develop and test the feasibility of a corn porridge meal fortified with papaya fruit extracts that have been shown to have antihelminthic properties. The investigators intend to evaluate its efficacy when given through school feeding programs and compare the outcome with albendazole- the recommended MDA agent for deworming school children. The investigators will design and formulate the product and test it among children in three primary schools in Western Kenya.

Full description

Background: Soil transmitted helminthes (STHs) are among the world's neglected tropical diseases. Morbidity due to STHs is greatest in school-age children who typically have the highest burden of infection. In 2001, WHO passed a resolution for the use of large-scale mass drug administration (MDA) to deworm vulnerable children. Though effective, there is concern that MDA might not be sustainable over extended periods. Additionally the current MDA strategy do not consider child malnutrition, a very common malady in resource limited countries. The investigators report a pilot evaluation of an innovation that bundles school feeding and deworming.

The investigators designed a maize (corn) flour fortified with grounded dried papaya (Carica papaya) seeds and used it to prepare porridge as per the usual school meal recipe. Children from three primary schools from Nandi County in Kenya were randomized into three arms: One school received 300 ml papaya fortified porridge daily (test school), a second school received similar serving of plain porridge without the pawpaw ingredient (placebo) and a third school received the placebo porridge and the conventional MDA approach of one time 400mg dosage of albendazole. Prior to the randomization, an initial baseline stool microscopy analysis was done to determine presence and intensity of intestinal worms. Core indicators of nutrition-height, weight and hemoglobin counts-were also assessed. The children were monitored daily for two months and final stool sample analysis and clinical monitoring done at the end of the study. Baseline and follow-up data were analyzed and compared through SAS version 9.1 statistical package.

Enrollment

326 patients

Sex

All

Ages

4 to 12 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Consenting parents and guardians

Exclusion criteria

  • children with known allergy to papaya fruit products

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

326 participants in 3 patient groups, including a placebo group

Papaya seed porridge
Experimental group
Description:
Arm receiving porridge fortified with dried papaya seeds (Ujiplus)
Treatment:
Dietary Supplement: Ujiplus
Albendazole and Plain porridge
Active Comparator group
Description:
Arm receiving the approved albendazole treatment of 400mg once with plain porridge daily (without papaya seeds)
Treatment:
Drug: Albendazole
Plain porridge
Placebo Comparator group
Description:
arm receiving 300ml plain porridge daily (without papaya seeds)
Treatment:
Dietary Supplement: uji

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems